As of May, 8 The EPS for Celldex Therapeutics, Inc. (CLDX) Expected At $-0.18

April 16, 2018 - By Andrea Pope

Investors expect Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s quarterly earnings on May, 8., RTT reports. The earnings per share diference is $0.10 or 35.71 % up from last years number. Previous year: $-0.28; Analysts forcast: $-0.18. Wall Street now sees 5.88 % negative EPS growth despite Celldex Therapeutics, Inc. last quarter’s EPS of $-0.17. CLDX reached $0.761 on during the last trading session after $1.389 change.Celldex Therapeutics, Inc. is downtrending after having declined 30.36% since April 17, 2017. CLDX has 29.03 million volume or 1953.60% up from normal. CLDX underperformed by 41.91% the S&P500.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

In total 4 analysts cover Celldex (NASDAQ:CLDX). “Buy” rating has 2, “Sell” are 0, while 2 are “Hold”. 50% are bullish. 4 are the (NASDAQ:CLDX)’s analyst reports since November 7, 2017 according to StockzIntelligence Inc. On Wednesday, December 6 the firm earned “Buy” rating by WBB Securities. On Tuesday, November 7 the rating was maintained by H.C. Wainwright with “Buy”. On Thursday, March 8 the stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) has “Hold” rating given by Jefferies. On Thursday, March 8 Leerink Swann maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) rating. Leerink Swann has “Market Perform” rating and $3 target.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics.The firm is valued at $107.36 million. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer.Last it reported negative earnings. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.